Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  11.00 25.0% 55.00 55.00 57.00 56.80 43.00 45.90 3,100,912 16:35:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.9 -1.0 - 141

Futura Medical Share Discussion Threads

Showing 20801 to 20819 of 21475 messages
Chat Pages: Latest  835  834  833  832  831  830  829  828  827  826  825  824  Older
DateSubjectAuthorDiscuss
02/4/2021
09:34
Please stop.Co-High and Atlantis are one of the same. For the avoidance of doubt, Riverwood and Atlantis are also one of the same. THE ATLANTIS GROUP.
trader00100
02/4/2021
09:27
Atlantis have given a 2 million pound investment in the form of warrants. Futura have already received 1.5million and as of yesterday received the other 500k. I assume you received something for your investment? Or did you just bank transfer Futura some cash?If you like warrants so much, buy some. I'm sure the market maker will oblige.
trader00100
01/4/2021
22:43
Brilliantly put, RV2.
organstop
01/4/2021
18:37
Why exercise Warrants now that have 4 years to expire? https://atlantis-investment.com/files/file/%E8%A5%BF%E6%B3%BDFactsheet202008_EN.pdf https://www.investopedia.com/terms/l/long-shortequity.asp “with 4-year expiration from the date of issue and an exercise price of GBP0.22 per warrant”
lbo
01/4/2021
18:22
As previously said https://www.investorvillage.com/smbd.asp?mb=16353&mn=6435&pt=msg&mid=13899702 LBO - 25 Mar 2021 - 11:44:31 - 9137 of 9255 Really? The way the Co-High financial deal was structured it has cost them nothing as they can sell on the loan to a fund that can short the shares all the way back down to the conversion price and then have no capital outlay on the loan. If the share price is kept above 30p then the loan converts at 20p into 7.5m shares. Sell 3m shares less above 50p and then get 7.5m later at 20p. And what new investor or shareholder would pay more then 20-30p based on that valuation deal in any upcoming placing? Co-High could also buy more in a discounted placing if they wanted any more shares or they just sit on the Futura contract without having to go to the cost of doing the China studies or launching it ever. Its a free bet for a investment company not a company that specialises in distribution of similar products in China. Unlike the CSD500 deal which was at least with a recognised company in Ansell and under a brand like Jissbon. But still that didn’t generate any Revenue for Futura. If we see similar small time distribution deals with MED300 as happened with CSD500 then we won’t see any significant upfront cash from those deals. So they need to do a placing. https://www.lewissilkin.com/en/insights/convertible-loan-notes-and-or-advance-subscription-agreements-as-a-source-of-emergency-funding-faqs https://www.agiocapsol.com/en/newsroom/agio-capital-business-solutions-successfully-supported-the-investment-in-uk-listed-company-futura-medical-and-joint-collaboration-for-greater-china-south-east-asia/ Agio introduced Futura Medical to potential Chinese strategic partners and investors and supported the financial transaction from Atlantis Investment Management as well as the negotiations with Co-High Investment Management. Our offering includes: Organise and schedule investor meetings or road shows
lbo
01/4/2021
17:58
Please read what you just wrote. I would suggest talking to a financial advisor.
trader00100
01/4/2021
17:51
Now the question after that RNS is will they be selling those shares in the market that they have just exercised at 22p? Or is there another reason why they have exercised those warrants so early? Then the next question is can they get Lombard to exercise their warrants from the last 8p fundraising. https://polaris.brighterir.com/public/futura_medical/news/rns/story/r7nozgw Lombard Odier will receive a total of 10,937,500 warrants to subscribe for further new Ordinary Shares at a price of 40 pence per share, exercisable until the fifth anniversary of their issue, in respect of its participation in the Subscription.
lbo
01/4/2021
08:35
Caveat Emptor https://www.investorschronicle.co.uk/shares/2019/12/13/avoid-aim-s-traps/ https://amp.ft.com/content/ea2bd724-140c-11e5-abda-00144feabdc0
lbo
01/4/2021
06:51
New ISA year soon, chance to grab more with new money, or bed and ISA for those fully invested.
glavey
31/3/2021
21:57
Always DYOR https://link.springer.com/article/10.1007/s10198-016-0820-3 Medical devices (MDs) often obtain market authorization with much less clinical evidence than other health technologies, especially pharmaceuticals. This is due to a number of reasons. First, in contrast to pharmaceuticals, there is no legal requirement to conduct adequately controlled clinical studies, other than for ‘high-risk’ devices in some jurisdictions. In the US for example, high-risk devices and innovative lower-risk devices are required to demonstrate ‘reasonable assurance of safety and effectiveness’, which may imply clinical evidence based on randomized studies in many instances. In contrast, in the EU the requirement is to demonstrate adequate performance and safety, which can often be achieved by conducting observational studies such as registries https://www.the-scientist.com/news-opinion/sec-charges-ubiome-founders-with-defrauding-investors-68583 https://www.thetimes.co.uk/article/ubiome-scandal-gives-silicon-valley-a-kick-in-the-guts-nmkdtj6kv
lbo
31/3/2021
19:10
Coming from an individual that has created hundreds of posts across multiple boards in a few days, totally contradicting his/her/it's previous posts. You must be the chairthing of the schizophrenia society.
j777j
31/3/2021
15:37
Yes you are doing a good job spamming all the boards with your team.How many different guises have you had on this board alone? If you are so pessimistic what on earth are you doing here?
j777j
31/3/2021
13:42
"The Company has now received initial offers from a number of parties and believes the EU approval of MED3000 will assist the Company in its objective of delivering long-term, sustainable value through the licensing of MED3000." Their words not mine. Furthermore, I do not believe in coincidences. "Assuming a smooth regulatory pathway, MED3000 would be the first clinically proven ED product that is approved OTC in Europe and the US. Its rapid onset of effect, undoubted safety, and ease of use suggest MED3000 would offer an attractive, clearly differentiated (not ‘me too’), and competitive clinical profile compared not only to the market leading class of PDE5 inhibitors, but other classes of competing ED therapies. Management has conducted market research analyses that suggest sales of $500m three years post-launch, rising to $584m by year five and $661m by year ten. " Trinity Delta EU was smooth and is done and dusted.CE mark is just a formality.
j777j
31/3/2021
13:10
Hi Super. No I gave that link in post 11472 but it was subsequently questioned by J777J “if a competitor had it written. It is after all a US publication” The follow up link was then posted by me as it gives some background about the author and why he questions published scientific literature under that name and not his real name. To use a football analogy and it applies on here. Attack the ball not the player otherwise it’s foul.
lbo
31/3/2021
12:41
LBO - was this the link you intended for 11478? The one you gave doesn't make much sense in context. https://www.discovermagazine.com/health/the-erection-of-a-placebo
supernumerary
31/3/2021
12:32
But no update on the EU certificate until at least May and no update on the patent for much longer? Ironic you accuse others of "innuendo" with "posts" like "newsflow is imminent" But there always two sides to every story.
lbo
31/3/2021
12:07
If they sign a deal they announce immediately,but nice try. You have spent hundreds of posts in a few days talking this down Always innuendo,the usual tactics.
j777j
31/3/2021
11:07
Anyway what we do know is.. "The Company has now received initial offers from a number of parties and believes the EU approval of MED3000 will assist the Company in its objective of delivering long-term, sustainable value through the licensing of MED3000." Also the Chinese have committed up to £6 million towards launching into China. They run a specialised health care fund and have put their money where their mouth is. I think I will add as newsflow is imminent on a number of fronts. ps Re Cannabidiol,you clearly havent done your research as those investors are experienced players.They set up a separate co specifically to JV with Fum. You are making it out as cloak and dagger when that is simply not the case.In any event they are working on a product which could become the key ingredient in all topically applied cannabidiol products.
j777j
31/3/2021
11:01
Yeah has some potential but they at very early days and needs a lot of capital to be invested. Like Kabey Pharma and CSD500 it does not inspire confidence when partners are unheard of and are only incorporating around the time the Futura deals are announced to the market https://cbderma-technology.com https://reportlet.co.uk/company/12133619/cbderma-technology-limited/ Also lot of risk in transdermal CBD https://news.bloomberglaw.com/esg/zynerba-experimental-cbd-company-sued-over-drug-trial-results
lbo
Chat Pages: Latest  835  834  833  832  831  830  829  828  827  826  825  824  Older
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210512 18:33:28